Neurogene Inc. - 8-K Filing

Neurogene reports Q3 2026 net loss of $29.0 million and anticipates Embolden trial topline data in 2H 2027 (Items: 2.02 and Exhibits 99)

3 articles from 1 source · updated November 9, 2026, 21:07 UTC

Coverage

• Immunome Inc. - 8-K Filing SEC EDGAR · November 9, 2026, 21:05 UTC
• AMC Global Media Inc. - 8-K Filing SEC EDGAR · November 9, 2026, 21:04 UTC
• Neurogene Inc. - 8-K Filing SEC EDGAR · November 9, 2026, 13:19 UTC